Palmoplantar Pustulosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major palmoplantar pustulosis markets reached a value of US$ 532.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,064.5 Million by 2034, exhibiting a growth rate (CAGR) of 6.51% during 2024-2034.
The palmoplantar pustulosis market has been comprehensively analyzed in IMARC's new report titled "Palmoplantar Pustulosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Palmoplantar pustulosis is a chronic skin disorder characterized by the formation of sterile pustules on the palms of the hands and soles of the feet. This condition usually presents painful, itchy, and inflamed pustules that can emerge in clusters, causing significant discomfort and impairment in daily activities. Some common symptoms of the illness include red, scaly patches on the palms and soles, followed by the development of pus-filled blisters. The pustules may eventually dry up and peel, leading to the formation of crusts, which can exacerbate discomfort and pain. The diagnosis of palmoplantar pustulosis typically involves a combination of a thorough physical examination and a review of the patient's medical history. The healthcare provider may also rely on clinical criteria, such as the appearance and distribution of pustules, to differentiate this disease from various other skin conditions. In some cases, a skin biopsy may be required to confirm the diagnosis of palmoplantar pustulosis.
The escalating prevalence of dermatological disorders resulting from immune system dysfunction, which causes the body's defense mechanism to mistakenly attack healthy skin cells, leading to inflammation and the formation of pustules, is primarily driving the palmoplantar pustulosis market. In addition to this, the inflating utilization of effective treatments, such as topical corticosteroids, retinoids, immunosuppressive agents, etc., to manage the symptoms of the ailment and prevent further exacerbations is creating a positive outlook for the market. Moreover, the widespread adoption of non-pharmacological interventions, including physical and occupational therapies, since they focus on boosting hand and foot function, reducing pain, and improving the quality of life for people suffering from the disease, is further bolstering the market growth. Apart from this, the rising usage of phototherapy, that involves the controlled exposure of the affected skin to ultraviolet (UV) light, thereby enhancing skin health and leading to a reduction in pustule formation, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced biological therapies, such as TNF-alpha inhibitors and phosphodiesterase-4 inhibitors, which are usually administered by injection or infusion to decrease the risk of systemic side effects in patients, is expected to drive the palmoplantar pustulosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the palmoplantar pustulosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for palmoplantar pustulosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the palmoplantar pustulosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the palmoplantar pustulosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the palmoplantar pustulosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current palmoplantar pustulosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the palmoplantar pustulosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the palmoplantar pustulosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the palmoplantar pustulosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of palmoplantar pustulosis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of palmoplantar pustulosis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of palmoplantar pustulosis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with palmoplantar pustulosis across the seven major markets?
What is the size of the palmoplantar pustulosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of palmoplantar pustulosis?
What will be the growth rate of patients across the seven major markets?
Palmoplantar Pustulosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for palmoplantar pustulosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the palmoplantar pustulosis market?
What are the key regulatory events related to the palmoplantar pustulosis market?
What is the structure of clinical trial landscape by status related to the palmoplantar pustulosis market?
What is the structure of clinical trial landscape by phase related to the palmoplantar pustulosis market?
What is the structure of clinical trial landscape by route of administration related to the palmoplantar pustulosis market?
The palmoplantar pustulosis market has been comprehensively analyzed in IMARC's new report titled "Palmoplantar Pustulosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Palmoplantar pustulosis is a chronic skin disorder characterized by the formation of sterile pustules on the palms of the hands and soles of the feet. This condition usually presents painful, itchy, and inflamed pustules that can emerge in clusters, causing significant discomfort and impairment in daily activities. Some common symptoms of the illness include red, scaly patches on the palms and soles, followed by the development of pus-filled blisters. The pustules may eventually dry up and peel, leading to the formation of crusts, which can exacerbate discomfort and pain. The diagnosis of palmoplantar pustulosis typically involves a combination of a thorough physical examination and a review of the patient's medical history. The healthcare provider may also rely on clinical criteria, such as the appearance and distribution of pustules, to differentiate this disease from various other skin conditions. In some cases, a skin biopsy may be required to confirm the diagnosis of palmoplantar pustulosis.
The escalating prevalence of dermatological disorders resulting from immune system dysfunction, which causes the body's defense mechanism to mistakenly attack healthy skin cells, leading to inflammation and the formation of pustules, is primarily driving the palmoplantar pustulosis market. In addition to this, the inflating utilization of effective treatments, such as topical corticosteroids, retinoids, immunosuppressive agents, etc., to manage the symptoms of the ailment and prevent further exacerbations is creating a positive outlook for the market. Moreover, the widespread adoption of non-pharmacological interventions, including physical and occupational therapies, since they focus on boosting hand and foot function, reducing pain, and improving the quality of life for people suffering from the disease, is further bolstering the market growth. Apart from this, the rising usage of phototherapy, that involves the controlled exposure of the affected skin to ultraviolet (UV) light, thereby enhancing skin health and leading to a reduction in pustule formation, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced biological therapies, such as TNF-alpha inhibitors and phosphodiesterase-4 inhibitors, which are usually administered by injection or infusion to decrease the risk of systemic side effects in patients, is expected to drive the palmoplantar pustulosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the palmoplantar pustulosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for palmoplantar pustulosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the palmoplantar pustulosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the palmoplantar pustulosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the palmoplantar pustulosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current palmoplantar pustulosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the palmoplantar pustulosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the palmoplantar pustulosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the palmoplantar pustulosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of palmoplantar pustulosis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of palmoplantar pustulosis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of palmoplantar pustulosis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with palmoplantar pustulosis across the seven major markets?
What is the size of the palmoplantar pustulosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of palmoplantar pustulosis?
What will be the growth rate of patients across the seven major markets?
Palmoplantar Pustulosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for palmoplantar pustulosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the palmoplantar pustulosis market?
What are the key regulatory events related to the palmoplantar pustulosis market?
What is the structure of clinical trial landscape by status related to the palmoplantar pustulosis market?
What is the structure of clinical trial landscape by phase related to the palmoplantar pustulosis market?
What is the structure of clinical trial landscape by route of administration related to the palmoplantar pustulosis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PALMOPLANTAR PUSTULOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PALMOPLANTAR PUSTULOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PALMOPLANTAR PUSTULOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PALMOPLANTAR PUSTULOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PALMOPLANTAR PUSTULOSIS - UNMET NEEDS
10 PALMOPLANTAR PUSTULOSIS - KEY ENDPOINTS OF TREATMENT
11 PALMOPLANTAR PUSTULOSIS - MARKETED PRODUCTS
11.1 List of Palmoplantar Pustulosis Marketed Drugs Across the Top 7 Markets
11.1.1 Tremfya (Guselkumab) - Janssen Biotech
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PALMOPLANTAR PUSTULOSIS - PIPELINE DRUGS
12.1 List of Palmoplantar Pustulosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Apremilast - Amgen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Imsidolimab - AnaptysBio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 KHK4827 - Kyowa Kirin
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PALMOPLANTAR PUSTULOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PALMOPLANTAR PUSTULOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PALMOPLANTAR PUSTULOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Palmoplantar Pustulosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Palmoplantar Pustulosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Palmoplantar Pustulosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Palmoplantar Pustulosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Palmoplantar Pustulosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Palmoplantar Pustulosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Palmoplantar Pustulosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Palmoplantar Pustulosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Palmoplantar Pustulosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Palmoplantar Pustulosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Palmoplantar Pustulosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Palmoplantar Pustulosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Palmoplantar Pustulosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Palmoplantar Pustulosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Palmoplantar Pustulosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Palmoplantar Pustulosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
16 PALMOPLANTAR PUSTULOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PALMOPLANTAR PUSTULOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PALMOPLANTAR PUSTULOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PALMOPLANTAR PUSTULOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PALMOPLANTAR PUSTULOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PALMOPLANTAR PUSTULOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PALMOPLANTAR PUSTULOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PALMOPLANTAR PUSTULOSIS - UNMET NEEDS
10 PALMOPLANTAR PUSTULOSIS - KEY ENDPOINTS OF TREATMENT
11 PALMOPLANTAR PUSTULOSIS - MARKETED PRODUCTS
11.1 List of Palmoplantar Pustulosis Marketed Drugs Across the Top 7 Markets
11.1.1 Tremfya (Guselkumab) - Janssen Biotech
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PALMOPLANTAR PUSTULOSIS - PIPELINE DRUGS
12.1 List of Palmoplantar Pustulosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Apremilast - Amgen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Imsidolimab - AnaptysBio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 KHK4827 - Kyowa Kirin
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PALMOPLANTAR PUSTULOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PALMOPLANTAR PUSTULOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PALMOPLANTAR PUSTULOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Palmoplantar Pustulosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Palmoplantar Pustulosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Palmoplantar Pustulosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Palmoplantar Pustulosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Palmoplantar Pustulosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Palmoplantar Pustulosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Palmoplantar Pustulosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Palmoplantar Pustulosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Palmoplantar Pustulosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Palmoplantar Pustulosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Palmoplantar Pustulosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Palmoplantar Pustulosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Palmoplantar Pustulosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Palmoplantar Pustulosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Palmoplantar Pustulosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Palmoplantar Pustulosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Palmoplantar Pustulosis - Access and Reimbursement Overview
16 PALMOPLANTAR PUSTULOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PALMOPLANTAR PUSTULOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PALMOPLANTAR PUSTULOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
